Sangamo Therapeutics Explained

Sangamo Therapeutics
Type:Public
Traded As:NASDAQ:
Russell 2000 Index component
Industry:Biotechnology
Founded:1995
Location City:Brisbane, California, US
Key People:Sandy Macrae (CEO)
Edward Rebar (CTO)
Assets: $562.5 million
Assets Year:2022
Equity: $294.958 million
Equity Year:2022
Num Employees:354
Revenue: $111.3 million
Revenue Year:2022
Operating Income: -$201.281 million
Income Year:2022
Net Income: $192.3 million
Net Income Year:2022
Footnotes:[1]

Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc.) is an American biotechnology company based in Brisbane, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.[2]

History

The company was founded in 1995 in Richmond, California.[3] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees. Sandy Macrae is the president.[4] In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.[5]

Research

Sangamo applies technology to treat haemophilia B and lysosomal storage diseases including mucopolysaccharidosis type I (Hurler Syndrome) and mucopolysaccharidosis type II (Hunter Syndrome). The FDA granted Sangamo fast track designation for SB-525, a gene therapy candidate for haemophilia A. In its partnership with Pfizer in 2017,[6] Sangamo uses Bioverativ in hemoglobinopathies such as beta thalassemia and sickle cell disease. It is also developing zinc finger gene editing technology.[7]

In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body" human gene editing therapy to permanently alter DNA - in a patient with Hunter syndrome.[8] clinical trials by Sangamo involving gene editing using zinc finger nuclease were ongoing.[9]

Clinical trials

Sangamo's programs are a mix of wholly owned and partnered; major partners include Pfizer, Biogen, Sanofi, Takeda, and Kite (a Gilead company).[10] [11] [12]

As of 2020 Sangamo had the following clinical trials underway in the US:

In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.[20]

See also

Notes and References

  1. Web site: Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results . 22 February 2023 . 24 February 2023 . Sangamo.
  2. News: Sangamo and new gene therapy partner Pfizer lifted by FDA fast track. McConaghie. Andrew. 2017-05-17. Pharmaphorum. 2018-10-01. en-GB.
  3. News: Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04. 2018-09-08. Equities. 2018-10-01. en-US.
  4. Ledford. Heidi. 2018-09-05. First test of in-body gene editing shows promise. Nature. EN. 10.1038/d41586-018-06195-6. 92840885 . 0028-0836.
  5. Web site: Sangamo Therapeutics appoints Edward Rebar as senior vice president. 2018-07-16. Post Online Media. Richmond, California. en. 2018-10-01.
  6. Web site: SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY Pfizer. www.pfizer.com. 2020-04-22.
  7. News: Sangamo's Zinc Fingers Fail Again. Time to Walk Away?. Renauer. Cory. 2018-09-06. The Motley Fool. 2018-10-01. en.
  8. News: Marchione . Marilyn . Tests suggest scientists achieved 1st 'in body' gene editing . 7 February 2019 . . 7 February 2019 .
  9. Web site: Staff . Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II . 2 February 2019 . . . 7 February 2019.
  10. Web site: SGMO.OQ - Sangamo Therapeutics Inc Profile Reuters. 2020-07-28. SGMO.OQ - Sangamo Therapeutics Inc Profile Reuters. en.
  11. Web site: Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates. 2020-07-29. FierceBiotech. en.
  12. Web site: Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news.. 2020-07-29. en.hdbuzz.net.
  13. Web site: A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  14. Web site: Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  15. Web site: A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  16. Web site: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  17. Web site: Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  18. Web site: Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  19. Web site: Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov. 2020-07-28. clinicaltrials.gov. en.
  20. News: 2023-02-23 . Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans . en . Fierce Biotech . 2023-02-24.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sangamo Therapeutics".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.